8
SECTION NAME
BIOTECHNOLOGY
reporter plasmid encoding green fluorescent protein (GFP) driven by a CMV promoter (pEGFP-N1, Clontech) was added to each cell suspension at a concentration of 20µg/ml. Aliquots of 200µl were then transferred into each of the wells of a 96-well electroporation plate and electroporated with the Gene Pulser MXcell system, Bio-Rad Laboratories Inc (Fig. 1).
Multiple cell types simultaneously tested
Holly Reynolds and David A Dean describe electroporation of smooth muscle cells using an electroporation system.
Holly Reynolds et David A Dean décrit l’électroporation du muscle lisse en ayant recours à un système d’électroporation.
Holly Reynolds und David A Dean erläutern die Elektroporation glatter Muskelzellen mithilfe einer Elektroporationsanlage.
S
mooth muscle cells (SMCs) lie at the centre of a number of pathologies
throughout the body, including vascular proliferative diseases such as atherosclerosis, restenosis, vein graft stenosis, and asthma. In order to study SMC biology in general and the mechanisms of pathogenesis of these diseases in particular, molecular manipulation of these cells is necessary. However, transfection of these cells, especially primary isolates from human origin, has been difficult. In this report, we have used the Gene Pulser MXcell lectroporation system to rapidly optimise experimental conditions for transfection of several SMC types.
Above The Gene Pulser MXcell system from Bio-Rad Laboratories Inc.
Te benefit of the Gene Pulser MXcell electroporation system is that it allows the user to optimise transfection protocols to multiple cell types at the same time, using a 96-well format. Using this system, we optimised transfection of three
www.scientistlive.com
different human SMC primary isolates: aortic intimal SMC, pulmonary artery SMC, and bronchial SMC.
Primary isolated human aortic intimal SMCs and human pulmonary artery SMCs were cultured in GIBCO Dulbecco’s Modified Eagle Medium (DMEM, Invitrogen Corporation) supplemented with 10 per cent fetal bovine serum (FBS). Bronchial SMCs were cultured in Smooth Muscle Basal Medium (SmBM, Lonza Group Ltd) at 37°C. Cells were passaged one day prior to electroporation, so at the time of electroporation the cells were approximately 80–90 per cent confluent and actively dividing. Cells were washed with phosphate buffered saline (PBS) and trypsinized. All three cell types were then centrifuged and resuspended in serum-free DMEM at a cell density of 2 x 106. A
After electroporation, the cells were transferred to 24-well culture plates, each well containing 2ml of DMEM with 10 per cent FBS or SmBM,and grown for 24hr at 37°C. At 24hr, cells were visualised by epifluorescence microscopy (Leica DMI 6000B, Leica Microsystems) and imaged using Volocity imaging software (PerkinElmer, Inc.) to detect GFP in electroporated cells. After imaging, cells were washed with PBS, trypsinized, and counted using trypan blue exclusion to determine viability. Samples were then spun, fixed in ice cold 1 per cent formaldehyde for 15 minutes, and resuspended in PBS in order to run them on a BD FACSCalibur flow cytometer (BD Biosciences) to detect GFP-expressing cells.
In order to optimise electroporation parameters for different types of SMCs, the Gene Pulser MXcell system was used to simultaneously test several parameters. Cell viability and transfection efficiency were recorded for each sample.
Voltage conditions between 150 and 450V were applied to the three types of SMC while capacitance was held constant at 350µF. All three SMC types had declined survival with increased voltage. Of the three cell types, SMCs from the pulmonary artery showed the greatest viability at all field strengths, with the aortic intimal SMCs showing intermediate viability and the bronchial SMCs being the most sensitive to increasing fields. Te transfection efficiency of the cell lines varied with the increasing voltage and there was generally a trade-off with cell survival vs. DNA delivery. For both aortic intimal and pulmonary
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36